Every 424B that Clene Inc. (CLNN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CLNN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLNN filings page.
Clene Inc. (CLNN) is conducting a primary offering of 1,219,513 shares of common stock at $3.28 per share under its S-3 shelf, raising approximately $4.0 million in gross proceeds, with no underwriting discounts or commissions, in a direct sale to certain existing stockholders, including directors and officers.
Shares outstanding will increase to 14,213,981, and about $2.1 million of the offering will be purchased by insiders. Net proceeds, together with existing cash, are planned primarily to support regulatory work and a planned NDA for lead drug candidate CNM-Au8, expanded access protocols, commercialization preparation and manufacturing expansion. Clene discloses recurring losses, limited cash, a minimum cash covenant on its 2024 senior secured convertible notes, and explicitly states there is substantial doubt about its ability to continue as a going concern absent additional financing.
Clene Inc. is offering 1,000,000 shares of common stock at an offering price of $7.00 per share pursuant to this prospectus supplement and the accompanying base prospectus. Delivery is expected on or about May 6, 2026. Net proceeds to the company are estimated at approximately $6,405,000 after underwriting discounts. The company states it will use proceeds to prepare and file an NDA for CNM-Au8, support ongoing expanded access protocols and a planned Phase 3 trial, expand manufacturing, and for general corporate purposes. The filing discloses substantial doubt about Clene’s ability to continue as a going concern: cash and cash equivalents were $5.2M as of December 31, 2025, operating losses were $23.1M for 2025, and the company expects to need additional financing within the next twelve months. The prospectus supplement also summarizes recent FDA feedback that NfL biomarker changes “may be capable of supporting” an NDA submission under the accelerated approval pathway in ALS and states the company intends to submit an NDA in Q3 2026.
Clene Inc. files a preliminary prospectus supplement under its Form S-3 shelf to offer shares of common stock (Nasdaq: CLNN), with aggregate shelf capacity of $160,000,000. The supplement does not state the number of shares or the public offering price per share; delivery and certain dates are left blank in this draft. The prospectus supplement describes use of proceeds for general corporate purposes, including funding clinical development of CNM-Au8, manufacturing and regulatory activities, and early-stage R&D.
The company reported 11,778,307 shares outstanding as of April 30, 2026. Financial context includes a loss from operations of $23.1M and cash and cash equivalents of $5.2M as of December 31, 2025, and the filing discloses substantial doubt about going concern and plans to seek additional financing.
Clene Inc. is offering 928,333 shares of common stock together with Series A and Series B warrants in units priced at $6.50, for gross proceeds of about $6.0 million and estimated net proceeds of approximately $5.7 million before any warrant exercises. Each unit includes one share, a Series A Warrant for stock at an initial $6.00 exercise price, and a Series B Warrant with step-up exercise prices tied to future FDA and share-price milestones, with the warrants expiring in three and five years, respectively, and subject to a call feature if they are in the money. After the offering, Clene expects 11,778,307 shares outstanding, assuming no warrant exercises, and plans to use the cash mainly to fund clinical and regulatory work for its lead ALS drug candidate CNM-Au8 and other R&D and corporate purposes. The company reports recurring losses, limited cash of $7.9 million as of September 30, 2025, senior secured convertible notes with a $2.0 million minimum cash covenant, and explicitly states there is substantial doubt about its ability to continue as a going concern.
Clene Inc. may offer and sell shares of common stock with a maximum aggregate gross sales price of up to $18,880,000 from time to time through Canaccord Genuity under its at‑the‑market program, as updated by Prospectus Supplement No. 3.
This amount excludes $6,119,859 of shares sold under prior supplements to date. Clene will receive the proceeds from any sales, and Canaccord may receive a commission of up to 3.0% of the gross sales price per share. The company notes it is no longer subject to the General Instruction I.B.6 sales limitations for its S‑3. On October 15, 2025, Nasdaq reported last sale prices of $8.89 for CLNN and $0.0102 for CLNNW.